Differences in Immunological Landscape between EGFR-Mutated and Wild-Type Lung Adenocarcinoma

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Immune checkpoint inhibitors (ICIs) show limited efficacy in lung adenocarcinoma patients with Epidermal Growth Factor Receptor (EGFR) mutations.
• The underlying mechanisms for this poor response remain unclear.
• Understanding the tumor microenvironment (TME) is crucial for optimizing cancer immunotherapy.

Purpose of the Study:

• To investigate and compare the TME characteristics between lung adenocarcinoma patients with and without EGFR mutations.
• To identify potential mechanisms explaining the differential response to ICIs based on EGFR mutation status.

Main Methods:

• Retrospective analysis of 323 lung adenocarcinoma patients (164 with EGFR mutations).
• Immunohistochemistry analysis of resected tumor tissues.
• Assessment of immune checkpoint molecules (PD1, PD-L1, LAG-3) and immune cells (CD3, CD4, CD8, Foxp3) within the TME.

Main Results:

• Significant differences in TME composition were observed between EGFR-mutant and wild-type tumors.
• EGFR-mutant tumors exhibited higher expression of CD3, CD4, PD-L1, and Foxp3 compared to wild-type tumors.
• EGFR-wild-type tumors showed a positive correlation with LAG3 and PD-1 expression.
• EGFR-wild-type patients had significantly longer disease-free survival (DFS) than EGFR-mutant patients (P=0.0065).

Conclusions:

• EGFR mutation status significantly influences the TME composition in lung adenocarcinoma.
• Distinct TME profiles in EGFR-mutant versus wild-type tumors may underlie the differential response to ICIs.
• These findings offer insights into the mechanisms of ICI resistance and inform future therapeutic strategies.